Deciphera Pharmaceuticals (NASDAQ: DCPH) has priced an underwritten public offering of 5,251,239 shares at $10.00 per share and pre-funded warrants for 9,748,761 shares at $9.99 each. The total gross proceeds are estimated at $150 million, before expenses. The offering is set to close on April 29, 2022. Proceeds will fund the development of vimseltinib for tenosynovial giant cell tumor patients, DCC-3116 combination studies, and the pan-RAF program, along with general working capital needs. J.P. Morgan and Jefferies are the joint book-running managers.
Deciphera Pharmaceuticals (NASDAQ: DCPH) plans to raise $150 million through an underwritten public offering of common stock and pre-funded warrants. The offering includes a 30-day option for underwriters to purchase an additional $22.5 million in shares. Funds will support the development of vimseltinib in a Phase 3 study for TGCT, clinical trials for DCC-3116, the pan-RAF program, and general working capital. The securities are offered under an effective registration statement, with J.P. Morgan and Jefferies acting as joint book-running managers.
Deciphera Pharmaceuticals announced promising preclinical data for DCC-3116, a ULK kinase inhibitor, in combination with KRASG12C inhibitors for non-small cell lung cancer (NSCLC). Presented at the AACR Annual Meeting 2022, results indicated that DCC-3116, when paired with sotorasib or adagrasib, achieved deeper and longer tumor regressions compared to these inhibitors alone. The data highlights DCC-3116's potential in overcoming drug resistance through autophagy inhibition. Further clinical trials are anticipated to confirm these findings.
Deciphera Pharmaceuticals (NASDAQ: DCPH) announced that Tucker Kelly, CFO, will participate in a fireside chat at the Barclays Global Healthcare Conference on March 16, 2022, at 4:20 PM ET in Miami. A live webcast will be available on Deciphera’s Investors page, with a replay archived for 90 days. Deciphera is focused on developing innovative medicines for cancer treatment, utilizing its unique switch-control kinase inhibitor platform. Their product, QINLOCK®, is approved in several markets, including the U.S. and Europe, for treating fourth-line GIST.
Deciphera Pharmaceuticals reported Q4 2021 revenue of $24.2 million, with a total of $96.1 million for the year. The company is launching QINLOCK® in Europe and progressing two pivotal clinical studies: MOTION for vimseltinib and initial DCC-3116 data expected in 2H 2022. Despite a net loss of $88.4 million in Q4, cash reserves totaled $327.6 million. Challenges include the restructuring and disappointing results from the INTRIGUE study, which did not meet its primary endpoint.
Deciphera Pharmaceuticals (NASDAQ: DCPH) announced that CEO Steve Hoerter will present at two upcoming investor conferences: the Guggenheim 2022 Oncology Virtual Conference on February 9, 2022, at 8:30 AM ET and the 11th Annual SVB Leerink Global Healthcare Conference on February 16, 2022, at 3:40 PM ET. Live webcasts of both events will be available on the company's website, with replays accessible for 90 days post-presentation. Deciphera focuses on developing innovative cancer treatments, including its approved QINLOCK® for fourth-line GIST in various regions, including the U.S.
Deciphera Pharmaceuticals (NASDAQ: DCPH) will release its fourth quarter and full year 2021 financial results on February 8, 2022, followed by a live conference call at 4:30 PM ET. Interested parties can join the call by dialing (866) 930-5479 or accessing the webcast on the company’s website. Deciphera focuses on developing innovative cancer therapies, including QINLOCK®, approved in several regions worldwide for treating fourth-line GIST.
Deciphera Pharmaceuticals (DCPH) has presented results from the INTRIGUE Phase 3 study of QINLOCK in GIST patients, showing that ripretinib's efficacy is comparable to sunitinib, although it did not meet its primary endpoint for superiority in progression-free survival (PFS). The study involved 453 patients and highlighted that ripretinib had a better safety profile, with fewer severe adverse events. Notably, the objective response rate for ripretinib was 23.9% in patients with KIT exon 11 mutations, outperforming sunitinib's 14.6%. QINLOCK remains approved for use in multiple regions.
Deciphera Pharmaceuticals (NASDAQ: DCPH) has highlighted significant milestones for 2022 during its presentation at the J.P. Morgan Healthcare Conference. The company is launching QINLOCK in Germany and transitioning to a paid access program in France. Key clinical programs include the Phase 3 MOTION study for vimseltinib in tenosynovial giant cell tumor patients and ongoing developments for DCC-3116, a novel kinase inhibitor. Results from pivotal studies are expected to be presented in 2022, underscoring the company's commitment to improving cancer treatment options.
Deciphera Pharmaceuticals (NASDAQ: DCPH) will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022, at 9:00 AM ET. The event will be accessible via live webcast on their website's "Events and Presentations" page. A replay will be available for 30 days post-event. Deciphera specializes in developing innovative cancer treatments, with QINLOCK approved in several regions including the US, EU, and Australia. For more details, visit www.deciphera.com.